ID   CP2A6_HUMAN             Reviewed;         494 AA.
AC   P11509; A7YAE5; B2R7F6; P00190; P10890; Q16803; Q4VAT9; Q4VAU0;
AC   Q4VAU1; Q9H1Z7; Q9UCU0; Q9UK48;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 3.
DT   10-MAY-2017, entry version 200.
DE   RecName: Full=Cytochrome P450 2A6;
DE            EC=1.14.13.-;
DE   AltName: Full=1,4-cineole 2-exo-monooxygenase;
DE   AltName: Full=CYPIIA6;
DE   AltName: Full=Coumarin 7-hydroxylase;
DE   AltName: Full=Cytochrome P450 IIA3;
DE   AltName: Full=Cytochrome P450(I);
GN   Name=CYP2A6; Synonyms=CYP2A3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ASN-29 AND TYR-392.
RC   TISSUE=Liver;
RX   PubMed=2726448; DOI=10.1093/nar/17.8.2907;
RA   Miles J.S., Bickmore W., Brook J.D., McLaren A.W., Meehan R.,
RA   Wolf C.R.;
RT   "Close linkage of the human cytochrome P450IIA and P450IIB gene
RT   subfamilies: implications for the assignment of substrate
RT   specificity.";
RL   Nucleic Acids Res. 17:2907-2917(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS HIS-160 AND TYR-392.
RC   TISSUE=Hepatocyte;
RX   PubMed=2748347; DOI=10.1093/nar/17.12.4888;
RA   Yamano S., Nagata K., Yamazoe Y., Kato R., Gelboin H.V.,
RA   Gonzalez F.J.;
RT   "cDNA and deduced amino acid sequences of human P450 IIA3 (CYP2A3).";
RL   Nucleic Acids Res. 17:4888-4888(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANTS HIS-160 AND TYR-392, AND
RP   CHARACTERIZATION OF VARIANT HIS-160.
RC   TISSUE=Hepatocyte;
RX   PubMed=2322567; DOI=10.1021/bi00457a031;
RA   Yamano S., Tatsuno J., Gonzalez F.J.;
RT   "The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human
RT   liver microsomes.";
RL   Biochemistry 29:1322-1329(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT TYR-392.
RC   TISSUE=Liver;
RA   Zhuge J., Qian Y., Xie H., Yu Y.;
RT   "Sequence of a new human cytochrome P450-2A6 cDNA.";
RL   Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT TYR-392.
RC   TISSUE=Mammary gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-160; CYS-203;
RP   MET-365; TYR-392; ASP-418 AND ASP-419.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2007) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT TYR-392.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS HIS-160; TYR-392
RP   AND ARG-476.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 1-20, FUNCTION, SUBCELLULAR LOCATION, INDUCTION,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=1889415; DOI=10.1111/j.1432-1033.1991.tb16212.x;
RA   Maurice M., Emiliani S., Dalet-Beluche I., Derancourt J., Lange R.;
RT   "Isolation and characterization of a cytochrome P450 of the IIA
RT   subfamily from human liver microsomes.";
RL   Eur. J. Biochem. 200:511-517(1991).
RN   [11]
RP   PROTEIN SEQUENCE OF 1-13, FUNCTION, SUBCELLULAR LOCATION, INDUCTION,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=1944238;
RA   Yun C.H., Shimada T., Guengerich F.P.;
RT   "Purification and characterization of human liver microsomal
RT   cytochrome P-450 2A6.";
RL   Mol. Pharmacol. 40:679-685(1991).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 116-164, AND VARIANT CYP2A6*6
RP   GLN-128.
RX   PubMed=11278503; DOI=10.1074/jbc.M009432200;
RA   Kitagawa K., Kunugita N., Kitagawa M., Kawamoto T.;
RT   "CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single
RT   amino acid substitution (R128Q) that inactivates enzymatic activity.";
RL   J. Biol. Chem. 276:17830-17835(2001).
RN   [13]
RP   PRELIMINARY NUCLEOTIDE SEQUENCE [MRNA] OF 163-494, AND VARIANT
RP   TYR-392.
RX   PubMed=3856261; DOI=10.1073/pnas.82.4.983;
RA   Phillips I.R., Shephard E.A., Ashworth A., Rabin B.R.;
RT   "Isolation and sequence of a human cytochrome P-450 cDNA clone.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:983-987(1985).
RN   [14]
RP   CATALYTIC ACTIVITY, FUNCTION AS 1,4-CINEOLE 2-EXO-MONOOXYGENASE, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11695850; DOI=10.1080/00498250110065595;
RA   Miyazawa M., Shindo M., Shimada T.;
RT   "Roles of cytochrome P450 3A enzymes in the 2-hydroxylation of 1,4-
RT   cineole, a monoterpene cyclic ether, by rat and human liver
RT   microsomes.";
RL   Xenobiotica 31:713-723(2001).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 29-494 IN COMPLEX WITH
RP   COUMARIN; HEME AND THE INHIBITOR METHOXSALEN, FUNCTION, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=16086027; DOI=10.1038/nsmb971;
RA   Yano J.K., Hsu M.H., Griffin K.J., Stout C.D., Johnson E.F.;
RT   "Structures of human microsomal cytochrome P450 2A6 complexed with
RT   coumarin and methoxsalen.";
RL   Nat. Struct. Mol. Biol. 12:822-823(2005).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 29-494 IN COMPLEX WITH
RP   PHENACETIN AND HEME, AND FUNCTION.
RX   PubMed=17125252; DOI=10.1021/jm060519r;
RA   Yano J.K., Denton T.T., Cerny M.A., Zhang X., Johnson E.F.,
RA   Cashman J.R.;
RT   "Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity,
RT   difference spectra, mechanism of inhibition, and protein
RT   cocrystallization.";
RL   J. Med. Chem. 49:6987-7001(2006).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 29-494 IN COMPLEX WITH
RP   PHENACETIN AND HEME, FUNCTION, CHARACTERIZATION OF VARIANTS LEU-110
RP   AND MET-365, AND MUTAGENESIS OF ILE-208; SER-213; ILE-300; GLY-301;
RP   SER-369 AND ARG-372.
RX   PubMed=18779312; DOI=10.1124/dmd.108.023770;
RA   DeVore N.M., Smith B.D., Urban M.J., Scott E.E.;
RT   "Key residues controlling phenacetin metabolism by human cytochrome
RT   P450 2A enzymes.";
RL   Drug Metab. Dispos. 36:2582-2590(2008).
RN   [19]
RP   CHARACTERIZATION OF VARIANT CYP2A6*2 HIS-160.
RX   PubMed=9409631; DOI=10.1016/S0278-6915(97)00066-5;
RA   Hadidi H., Zahlsen K., Idle J.R., Cholerton S.;
RT   "A single amino acid substitution (Leu160His) in cytochrome P450
RT   CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of
RT   coumarin.";
RL   Food Chem. Toxicol. 35:903-907(1997).
RN   [20]
RP   VARIANT CYP2A6*5 VAL-479.
RX   PubMed=10544257; DOI=10.1016/S0014-5793(99)01364-2;
RA   Oscarson M., McLellan R.A., Gullsten H., Agundez J.A., Benitez J.,
RA   Rautio A., Raunio H., Pelkonen O., Ingelman-Sundberg M.;
RT   "Identification and characterisation of novel polymorphisms in the
RT   CYP2A locus: implications for nicotine metabolism.";
RL   FEBS Lett. 460:321-327(1999).
RN   [21]
RP   VARIANTS CYP2A6*7 THR-471 AND CYP2A6*8 LEU-485.
RX   PubMed=11237731; DOI=10.1006/bbrc.2001.4422;
RA   Ariyoshi N., Sawamura Y., Kamataki T.;
RT   "A novel single nucleotide polymorphism altering stability and
RT   activity of CYP2a6.";
RL   Biochem. Biophys. Res. Commun. 281:810-814(2001).
RN   [22]
RP   VARIANTS CYP2A6*13 ARG-5; CYP2A6*14 ASN-29; CYP2A6*15 GLU-194 AND
RP   CYP2A6*16 SER-203.
RX   PubMed=15618701; DOI=10.2133/dmpk.17.482;
RA   Kiyotani K., Fujieda M., Yamazaki H., Shimada T., Guengerich F.P.,
RA   Parkinson A., Nakagawa K., Ishizaki T., Kamataki T.;
RT   "Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6
RT   gene in Japanese and Caucasians.";
RL   Drug Metab. Pharmacokinet. 17:482-487(2002).
RN   [23]
RP   VARIANTS ASP-419 AND THR-471.
RX   PubMed=12721789; DOI=10.1007/s10038-003-0021-7;
RA   Saito S., Iida A., Sekine A., Kawauchi S., Higuchi S., Ogawa C.,
RA   Nakamura Y.;
RT   "Catalog of 680 variations among eight cytochrome p450 (CYP) genes,
RT   nine esterase genes, and two other genes in the Japanese population.";
RL   J. Hum. Genet. 48:249-270(2003).
RN   [24]
RP   VARIANTS ARG-5; ASN-29; LEU-118; GLN-128; PRO-224; MET-365; ASP-418;
RP   ASP-419; THR-471; ARG-476 AND LEU-485.
RX   PubMed=15469410; DOI=10.1517/14622416.5.7.895;
RA   Solus J.F., Arietta B.J., Harris J.R., Sexton D.P., Steward J.Q.,
RA   McMunn C., Ihrie P., Mehall J.M., Edwards T.L., Dawson E.P.;
RT   "Genetic variation in eleven phase I drug metabolism genes in an
RT   ethnically diverse population.";
RL   Pharmacogenomics 5:895-931(2004).
RN   [25]
RP   VARIANTS LEU-110; LEU-118; LEU-128; ALA-131; ASP-418; ASP-419 AND
RP   TYR-438.
RX   PubMed=18360915; DOI=10.1002/humu.20698;
RA   Mwenifumbo J.C., Al Koudsi N., Ho M.K., Zhou Q., Hoffmann E.B.,
RA   Sellers E.M., Tyndale R.F.;
RT   "Novel and established CYP2A6 alleles impair in vivo nicotine
RT   metabolism in a population of Black African descent.";
RL   Hum. Mutat. 29:679-688(2008).
RN   [26]
RP   VARIANTS CYS-203; SER-203 AND MET-365, AND CHARACTERIZATION OF VARIANT
RP   CYS-203.
RX   PubMed=18216723; DOI=10.1097/FPC.0b013e3282f3606e;
RA   Ho M.K., Mwenifumbo J.C., Zhao B., Gillam E.M., Tyndale R.F.;
RT   "A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro
RT   and in vivo and decreases smoking in a population of Black-African
RT   descent.";
RL   Pharmacogenet. Genomics 18:67-75(2008).
CC   -!- FUNCTION: Exhibits a high coumarin 7-hydroxylase activity. Can act
CC       in the hydroxylation of the anti-cancer drugs cyclophosphamide and
CC       ifosphamide. Competent in the metabolic activation of aflatoxin
CC       B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-
CC       cineole 2-exo-monooxygenase. Possesses low phenacetin O-
CC       deethylation activity. {ECO:0000269|PubMed:11695850,
CC       ECO:0000269|PubMed:16086027, ECO:0000269|PubMed:17125252,
CC       ECO:0000269|PubMed:18779312, ECO:0000269|PubMed:1889415,
CC       ECO:0000269|PubMed:1944238}.
CC   -!- CATALYTIC ACTIVITY: 1,4-cineole + NADPH + O(2) = 2-exo-hydroxy-
CC       1,4-cineole + NADP(+) + H(2)O. {ECO:0000269|PubMed:11695850}.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.23 uM for coumarin {ECO:0000269|PubMed:11695850,
CC         ECO:0000269|PubMed:16086027};
CC         KM=530 uM for 1,4-cineole {ECO:0000269|PubMed:11695850,
CC         ECO:0000269|PubMed:16086027};
CC         Vmax=3.5 nmol/min/nmol enzyme toward 2-exo-hydroxy-1,4-cineole
CC         {ECO:0000269|PubMed:11695850, ECO:0000269|PubMed:16086027};
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Peripheral
CC       membrane protein. Microsome membrane; Peripheral membrane protein.
CC   -!- TISSUE SPECIFICITY: Liver. {ECO:0000269|PubMed:1889415,
CC       ECO:0000269|PubMed:1944238}.
CC   -!- INDUCTION: By phenobarbital and dexamethasone.
CC       {ECO:0000269|PubMed:1889415, ECO:0000269|PubMed:1944238}.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA52147.1; Type=Miscellaneous discrepancy; Note=Numerous conflicts and frameshifts.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Cytochrome P450 Allele Nomenclature Committee;
CC       Note=CYP2A6 alleles;
CC       URL="http://www.cypalleles.ki.se/cyp2a6.htm";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cyp2a6/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CYP2A6 entry;
CC       URL="https://en.wikipedia.org/wiki/CYP2A6";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CYP2A6ID40240ch19q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X13897; CAA32097.1; -; mRNA.
DR   EMBL; X13929; CAA32117.1; -; mRNA.
DR   EMBL; X13930; CAA32118.1; -; mRNA.
DR   EMBL; M33318; AAA52067.1; -; mRNA.
DR   EMBL; AF182275; AAF13600.1; -; mRNA.
DR   EMBL; AK312964; BAG35803.1; -; mRNA.
DR   EMBL; EU135979; ABV02584.1; -; Genomic_DNA.
DR   EMBL; FJ440681; ACK44068.1; -; Genomic_DNA.
DR   EMBL; AC008537; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471126; EAW57012.1; -; Genomic_DNA.
DR   EMBL; BC096253; AAH96253.3; -; mRNA.
DR   EMBL; BC096254; AAH96254.1; -; mRNA.
DR   EMBL; BC096255; AAH96255.1; -; mRNA.
DR   EMBL; BC096256; AAH96256.1; -; mRNA.
DR   EMBL; AF326721; AAG45229.1; -; Genomic_DNA.
DR   EMBL; K03192; AAA52147.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS12568.1; -.
DR   PIR; A00190; O4HUPB.
DR   PIR; S04698; O4HUA6.
DR   RefSeq; NP_000753.3; NM_000762.5.
DR   UniGene; Hs.250615; -.
DR   PDB; 1Z10; X-ray; 1.90 A; A/B/C/D=29-494.
DR   PDB; 1Z11; X-ray; 2.05 A; A/B/C/D=29-494.
DR   PDB; 2FDU; X-ray; 1.85 A; A/B/C/D=29-494.
DR   PDB; 2FDV; X-ray; 1.65 A; A/B/C/D=29-494.
DR   PDB; 2FDW; X-ray; 2.05 A; A/B/C/D=29-494.
DR   PDB; 2FDY; X-ray; 1.95 A; A/B/C/D=29-494.
DR   PDB; 3EBS; X-ray; 2.15 A; A/B/C/D=29-494.
DR   PDB; 3T3Q; X-ray; 2.10 A; A/B/C/D=29-494.
DR   PDB; 3T3R; X-ray; 2.40 A; A/B/C/D=29-494.
DR   PDB; 4EJJ; X-ray; 2.30 A; A/B/C/D=29-494.
DR   PDB; 4RUI; X-ray; 2.61 A; A/B/C/D/E/F=29-494.
DR   PDBsum; 1Z10; -.
DR   PDBsum; 1Z11; -.
DR   PDBsum; 2FDU; -.
DR   PDBsum; 2FDV; -.
DR   PDBsum; 2FDW; -.
DR   PDBsum; 2FDY; -.
DR   PDBsum; 3EBS; -.
DR   PDBsum; 3T3Q; -.
DR   PDBsum; 3T3R; -.
DR   PDBsum; 4EJJ; -.
DR   PDBsum; 4RUI; -.
DR   ProteinModelPortal; P11509; -.
DR   SMR; P11509; -.
DR   BioGrid; 107927; 4.
DR   STRING; 9606.ENSP00000301141; -.
DR   BindingDB; P11509; -.
DR   ChEMBL; CHEMBL5282; -.
DR   DrugBank; DB07621; (5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE.
DR   DrugBank; DB04665; 2H-1-BENZOPYRAN-2-ONE.
DR   DrugBank; DB00316; Acetaminophen.
DR   DrugBank; DB01118; Amiodarone.
DR   DrugBank; DB00381; Amlodipine.
DR   DrugBank; DB01351; Amobarbital.
DR   DrugBank; DB00182; Amphetamine.
DR   DrugBank; DB01435; Antipyrine.
DR   DrugBank; DB01274; Arformoterol.
DR   DrugBank; DB00972; Azelastine.
DR   DrugBank; DB00207; Azithromycin.
DR   DrugBank; DB00921; Buprenorphine.
DR   DrugBank; DB01156; Bupropion.
DR   DrugBank; DB00356; Chlorzoxazone.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB00604; Cisapride.
DR   DrugBank; DB00636; Clofibrate.
DR   DrugBank; DB00882; Clomifene.
DR   DrugBank; DB00257; Clotrimazole.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00531; Cyclophosphamide.
DR   DrugBank; DB06292; Dapagliflozin.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB01234; Dexamethasone.
DR   DrugBank; DB01191; Dexfenfluramine.
DR   DrugBank; DB00255; Diethylstilbestrol.
DR   DrugBank; DB00470; Dronabinol.
DR   DrugBank; DB00216; Eletriptan.
DR   DrugBank; DB04953; Ezogabine.
DR   DrugBank; DB04841; Flunarizine.
DR   DrugBank; DB01544; Flunitrazepam.
DR   DrugBank; DB00544; Fluorouracil.
DR   DrugBank; DB00690; Flurazepam.
DR   DrugBank; DB01213; Fomepizole.
DR   DrugBank; DB00983; Formoterol.
DR   DrugBank; DB01159; Halothane.
DR   DrugBank; DB01181; Ifosfamide.
DR   DrugBank; DB00951; Isoniazid.
DR   DrugBank; DB01026; Ketoconazole.
DR   DrugBank; DB01006; Letrozole.
DR   DrugBank; DB00281; Lidocaine.
DR   DrugBank; DB04871; Lorcaserin.
DR   DrugBank; DB01043; Memantine.
DR   DrugBank; DB00170; Menadione.
DR   DrugBank; DB00763; Methimazole.
DR   DrugBank; DB00553; Methoxsalen.
DR   DrugBank; DB01028; Methoxyflurane.
DR   DrugBank; DB01011; Metyrapone.
DR   DrugBank; DB01110; Miconazole.
DR   DrugBank; DB00471; Montelukast.
DR   DrugBank; DB07617; N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE.
DR   DrugBank; DB00238; Nevirapine.
DR   DrugBank; DB00184; Nicotine.
DR   DrugBank; DB01115; Nifedipine.
DR   DrugBank; DB06712; Nilvadipine.
DR   DrugBank; DB01059; Norfloxacin.
DR   DrugBank; DB00312; Pentobarbital.
DR   DrugBank; DB03783; Phenacetin.
DR   DrugBank; DB01174; Phenobarbital.
DR   DrugBank; DB01085; Pilocarpine.
DR   DrugBank; DB04977; Plitidepsin.
DR   DrugBank; DB00860; Prednisolone.
DR   DrugBank; DB00396; Progesterone.
DR   DrugBank; DB00818; Propofol.
DR   DrugBank; DB01045; Rifampicin.
DR   DrugBank; DB00412; Rosiglitazone.
DR   DrugBank; DB01037; Selegiline.
DR   DrugBank; DB01236; Sevoflurane.
DR   DrugBank; DB06729; Sulfaphenazole.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugBank; DB00752; Tranylcypromine.
DR   DrugBank; DB00755; Tretinoin.
DR   DrugBank; DB01361; Troleandomycin.
DR   DrugBank; DB00313; Valproic Acid.
DR   DrugBank; DB09068; Vortioxetine.
DR   DrugBank; DB00495; Zidovudine.
DR   GuidetoPHARMACOLOGY; 1321; -.
DR   iPTMnet; P11509; -.
DR   PhosphoSitePlus; P11509; -.
DR   BioMuta; CYP2A6; -.
DR   DMDM; 308153612; -.
DR   PaxDb; P11509; -.
DR   PeptideAtlas; P11509; -.
DR   PRIDE; P11509; -.
DR   DNASU; 1548; -.
DR   Ensembl; ENST00000301141; ENSP00000301141; ENSG00000255974.
DR   GeneID; 1548; -.
DR   KEGG; hsa:1548; -.
DR   UCSC; uc002opl.4; human.
DR   CTD; 1548; -.
DR   DisGeNET; 1548; -.
DR   GeneCards; CYP2A6; -.
DR   HGNC; HGNC:2610; CYP2A6.
DR   HPA; HPA046713; -.
DR   HPA; HPA047262; -.
DR   MalaCards; CYP2A6; -.
DR   MIM; 122720; gene+phenotype.
DR   neXtProt; NX_P11509; -.
DR   PharmGKB; PA121; -.
DR   eggNOG; KOG0156; Eukaryota.
DR   eggNOG; COG2124; LUCA.
DR   HOVERGEN; HBG015789; -.
DR   InParanoid; P11509; -.
DR   KO; K17683; -.
DR   PhylomeDB; P11509; -.
DR   TreeFam; TF352043; -.
DR   BioCyc; MetaCyc:HS10343-MONOMER; -.
DR   BRENDA; 1.14.14.1; 2681.
DR   Reactome; R-HSA-211981; Xenobiotics.
DR   Reactome; R-HSA-211999; CYP2E1 reactions.
DR   SABIO-RK; P11509; -.
DR   EvolutionaryTrace; P11509; -.
DR   GeneWiki; CYP2A6; -.
DR   GenomeRNAi; 1548; -.
DR   PRO; PR:P11509; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000255974; -.
DR   ExpressionAtlas; P11509; baseline and differential.
DR   Genevisible; P11509; HS.
DR   GO; GO:0005881; C:cytoplasmic microtubule; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031090; C:organelle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008392; F:arachidonic acid epoxygenase activity; IBA:GO_Central.
DR   GO; GO:0008389; F:coumarin 7-hydroxylase activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0016712; F:oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; IEA:InterPro.
DR   GO; GO:0046226; P:coumarin catabolic process; IDA:BHF-UCL.
DR   GO; GO:0009804; P:coumarin metabolic process; IDA:BHF-UCL.
DR   GO; GO:0017144; P:drug metabolic process; IDA:BHF-UCL.
DR   GO; GO:0019373; P:epoxygenase P450 pathway; IBA:GO_Central.
DR   GO; GO:0042738; P:exogenous drug catabolic process; IDA:BHF-UCL.
DR   GO; GO:0008202; P:steroid metabolic process; IMP:BHF-UCL.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002401; Cyt_P450_E_grp-I.
DR   InterPro; IPR008067; Cyt_P450_E_grp-I_CYP2A-like.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00463; EP450I.
DR   PRINTS; PR01684; EP450ICYP2A.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   Endoplasmic reticulum; Heme; Iron; Membrane; Metal-binding; Microsome;
KW   Monooxygenase; NADP; Oxidoreductase; Polymorphism; Reference proteome.
FT   CHAIN         1    494       Cytochrome P450 2A6.
FT                                /FTId=PRO_0000051668.
FT   METAL       439    439       Iron (heme axial ligand).
FT   BINDING     107    107       Substrate. {ECO:0000305}.
FT   BINDING     297    297       Substrate.
FT   VARIANT       5      5       G -> R (in allele CYP2A6*13;
FT                                dbSNP:rs28399434).
FT                                {ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|PubMed:15618701}.
FT                                /FTId=VAR_018330.
FT   VARIANT      29     29       S -> N (in allele CYP2A6*14;
FT                                dbSNP:rs28399435).
FT                                {ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|PubMed:15618701,
FT                                ECO:0000269|PubMed:2726448}.
FT                                /FTId=VAR_018331.
FT   VARIANT     110    110       V -> L (in allele CYP2A6*24; increases
FT                                phenacetin O-deethylation activity 4
FT                                fold; dbSNP:rs72549435).
FT                                {ECO:0000269|PubMed:18360915,
FT                                ECO:0000269|PubMed:18779312}.
FT                                /FTId=VAR_055035.
FT   VARIANT     118    118       F -> L (in allele CYP2A6*25 and allele
FT                                CYP2A6*26; dbSNP:rs28399440).
FT                                {ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|PubMed:18360915}.
FT                                /FTId=VAR_024711.
FT   VARIANT     128    128       R -> L (in allele CYP2A6*26).
FT                                {ECO:0000269|PubMed:18360915}.
FT                                /FTId=VAR_055036.
FT   VARIANT     128    128       R -> Q (in allele CYP2A6*6; loss of
FT                                activity; dbSNP:rs4986891).
FT                                {ECO:0000269|PubMed:11278503,
FT                                ECO:0000269|PubMed:15469410}.
FT                                /FTId=VAR_011577.
FT   VARIANT     131    131       S -> A (in allele CYP2A6*26;
FT                                dbSNP:rs59552350).
FT                                {ECO:0000269|PubMed:18360915}.
FT                                /FTId=VAR_055037.
FT   VARIANT     160    160       L -> H (in allele CYP2A6*2; unable to
FT                                catalyze 7-hydroxylation of coumarin;
FT                                causes switching from coumarin 7-
FT                                hydroxylation to 3-hydroxylation;
FT                                dbSNP:rs1801272).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:2322567,
FT                                ECO:0000269|PubMed:2748347,
FT                                ECO:0000269|PubMed:9409631,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_001249.
FT   VARIANT     194    194       K -> E (in allele CYP2A6*15).
FT                                {ECO:0000269|PubMed:15618701}.
FT                                /FTId=VAR_018332.
FT   VARIANT     203    203       R -> C (in allele CYP2A6*23; greatly
FT                                reduced activity toward nicotine C-
FT                                oxidation as well as reduced coumarin 7-
FT                                hydroxylation; dbSNP:rs56256500).
FT                                {ECO:0000269|PubMed:18216723,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_055034.
FT   VARIANT     203    203       R -> S (in allele CYP2A6*16;
FT                                dbSNP:rs56256500).
FT                                {ECO:0000269|PubMed:15618701,
FT                                ECO:0000269|PubMed:18216723}.
FT                                /FTId=VAR_018333.
FT   VARIANT     224    224       S -> P (in dbSNP:rs111033610).
FT                                {ECO:0000269|PubMed:15469410}.
FT                                /FTId=VAR_024712.
FT   VARIANT     292    292       V -> M (in dbSNP:rs2644906).
FT                                /FTId=VAR_059149.
FT   VARIANT     294    294       T -> S (in dbSNP:rs4997557).
FT                                /FTId=VAR_048448.
FT   VARIANT     365    365       V -> M (in allele CYP2A6*17, increases
FT                                phenacetin O-deethylation activity 2
FT                                fold; dbSNP:rs28399454).
FT                                {ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|PubMed:18216723,
FT                                ECO:0000269|PubMed:18779312,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_024713.
FT   VARIANT     392    392       F -> Y (in dbSNP:rs1809810).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:2322567,
FT                                ECO:0000269|PubMed:2726448,
FT                                ECO:0000269|PubMed:2748347,
FT                                ECO:0000269|PubMed:3856261,
FT                                ECO:0000269|Ref.4, ECO:0000269|Ref.6,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_055033.
FT   VARIANT     418    418       N -> D (in allele CYP2A6*28;
FT                                dbSNP:rs28399463).
FT                                {ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|PubMed:18360915,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_024714.
FT   VARIANT     419    419       E -> D (in allele CYP2A6*28;
FT                                dbSNP:rs8192730).
FT                                {ECO:0000269|PubMed:12721789,
FT                                ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|PubMed:18360915,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_018375.
FT   VARIANT     438    438       N -> Y (in allele CYP2A6*24).
FT                                {ECO:0000269|PubMed:18360915}.
FT                                /FTId=VAR_055038.
FT   VARIANT     471    471       I -> T (in allele CYP2A6*7;
FT                                dbSNP:rs5031016).
FT                                {ECO:0000269|PubMed:11237731,
FT                                ECO:0000269|PubMed:12721789,
FT                                ECO:0000269|PubMed:15469410}.
FT                                /FTId=VAR_011578.
FT   VARIANT     476    476       K -> R (in dbSNP:rs6413474).
FT                                {ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_024715.
FT   VARIANT     479    479       G -> V (in allele CYP2A6*5; loss of
FT                                activity; dbSNP:rs5031017).
FT                                {ECO:0000269|PubMed:10544257}.
FT                                /FTId=VAR_008356.
FT   VARIANT     485    485       R -> L (in allele CYP2A6*8;
FT                                dbSNP:rs28399468).
FT                                {ECO:0000269|PubMed:11237731,
FT                                ECO:0000269|PubMed:15469410}.
FT                                /FTId=VAR_011579.
FT   MUTAGEN     208    208       I->S: Increases phenacetin O-deethylation
FT                                activity 10 fold; when associated with F-
FT                                300 and A-301. Increases phenacetin O-
FT                                deethylation activity 38 fold; when
FT                                associated with F-300; A-301 and G-369.
FT                                {ECO:0000269|PubMed:18779312}.
FT   MUTAGEN     213    213       S->A: No effect on phenacetin O-
FT                                deethylation activity.
FT                                {ECO:0000269|PubMed:18779312}.
FT   MUTAGEN     300    300       I->F: Increases phenacetin O-deethylation
FT                                activity 3 fold. Increases phenacetin O-
FT                                deethylation activity 8 fold; when
FT                                associated with A-301. Increases
FT                                phenacetin O-deethylation activity 10
FT                                fold; when associated with S-208 and A-
FT                                301. Increases phenacetin O-deethylation
FT                                activity 12 fold; when associated with A-
FT                                301 and G-369. Increases phenacetin O-
FT                                deethylation activity 38 fold; when
FT                                associated with S-208; A-301 and G-369.
FT                                {ECO:0000269|PubMed:18779312}.
FT   MUTAGEN     301    301       G->A: Slightly decreases phenacetin O-
FT                                deethylation activity. Increases
FT                                phenacetin O-deethylation activity 8
FT                                fold; when associated with F-300.
FT                                Increases phenacetin O-deethylation
FT                                activity 10 fold; when associated with S-
FT                                208 and F-300. Increases phenacetin O-
FT                                deethylation activity 12 fold; when
FT                                associated with F-300 and G-369.
FT                                Increases phenacetin O-deethylation
FT                                activity 38 fold; when associated with S-
FT                                208; F-300 and G-369.
FT                                {ECO:0000269|PubMed:18779312}.
FT   MUTAGEN     369    369       S->G: Increases phenacetin O-deethylation
FT                                activity 3 fold. Increases phenacetin O-
FT                                deethylation activity 38 fold; when
FT                                associated with S-208; F-300 and A-301.
FT                                {ECO:0000269|PubMed:18779312}.
FT   MUTAGEN     372    372       R->H: Increases phenacetin O-deethylation
FT                                activity 2 fold.
FT                                {ECO:0000269|PubMed:18779312}.
FT   CONFLICT      3      7       Missing (in Ref. 1; CAA32097).
FT                                {ECO:0000305}.
FT   CONFLICT    255    255       N -> K (in Ref. 1; CAA32097).
FT                                {ECO:0000305}.
FT   CONFLICT    326    326       K -> Q (in Ref. 1; CAA32097).
FT                                {ECO:0000305}.
FT   TURN         41     43       {ECO:0000244|PDB:2FDV}.
FT   HELIX        46     48       {ECO:0000244|PDB:2FDV}.
FT   HELIX        51     53       {ECO:0000244|PDB:2FDU}.
FT   HELIX        54     65       {ECO:0000244|PDB:2FDV}.
FT   STRAND       67     73       {ECO:0000244|PDB:2FDV}.
FT   STRAND       76     81       {ECO:0000244|PDB:2FDV}.
FT   HELIX        84     91       {ECO:0000244|PDB:2FDV}.
FT   TURN         92     98       {ECO:0000244|PDB:2FDV}.
FT   HELIX       105    111       {ECO:0000244|PDB:2FDV}.
FT   STRAND      115    118       {ECO:0000244|PDB:2FDV}.
FT   HELIX       121    137       {ECO:0000244|PDB:2FDV}.
FT   TURN        138    141       {ECO:0000244|PDB:2FDV}.
FT   HELIX       143    162       {ECO:0000244|PDB:2FDV}.
FT   TURN        163    165       {ECO:0000244|PDB:2FDV}.
FT   HELIX       171    187       {ECO:0000244|PDB:2FDV}.
FT   HELIX       196    212       {ECO:0000244|PDB:2FDV}.
FT   HELIX       215    227       {ECO:0000244|PDB:2FDV}.
FT   STRAND      230    232       {ECO:0000244|PDB:2FDY}.
FT   HELIX       233    256       {ECO:0000244|PDB:2FDV}.
FT   HELIX       267    277       {ECO:0000244|PDB:2FDV}.
FT   TURN        278    280       {ECO:0000244|PDB:2FDV}.
FT   HELIX       288    319       {ECO:0000244|PDB:2FDV}.
FT   HELIX       321    334       {ECO:0000244|PDB:2FDV}.
FT   STRAND      337    339       {ECO:0000244|PDB:2FDV}.
FT   HELIX       343    348       {ECO:0000244|PDB:2FDV}.
FT   HELIX       350    363       {ECO:0000244|PDB:2FDV}.
FT   STRAND      378    380       {ECO:0000244|PDB:2FDV}.
FT   STRAND      383    385       {ECO:0000244|PDB:2FDV}.
FT   STRAND      390    393       {ECO:0000244|PDB:2FDV}.
FT   HELIX       395    399       {ECO:0000244|PDB:2FDV}.
FT   TURN        402    404       {ECO:0000244|PDB:2FDV}.
FT   STRAND      405    407       {ECO:0000244|PDB:4RUI}.
FT   HELIX       413    416       {ECO:0000244|PDB:2FDV}.
FT   STRAND      419    421       {ECO:0000244|PDB:3T3Q}.
FT   HELIX       442    459       {ECO:0000244|PDB:2FDV}.
FT   STRAND      460    466       {ECO:0000244|PDB:2FDV}.
FT   HELIX       468    470       {ECO:0000244|PDB:2FDV}.
FT   STRAND      476    483       {ECO:0000244|PDB:2FDV}.
FT   STRAND      489    493       {ECO:0000244|PDB:2FDV}.
SQ   SEQUENCE   494 AA;  56501 MW;  8C05CBF0EFC698AF CRC64;
     MLASGMLLVA LLVCLTVMVL MSVWQQRKSK GKLPPGPTPL PFIGNYLQLN TEQMYNSLMK
     ISERYGPVFT IHLGPRRVVV LCGHDAVREA LVDQAEEFSG RGEQATFDWV FKGYGVVFSN
     GERAKQLRRF SIATLRDFGV GKRGIEERIQ EEAGFLIDAL RGTGGANIDP TFFLSRTVSN
     VISSIVFGDR FDYKDKEFLS LLRMMLGIFQ FTSTSTGQLY EMFSSVMKHL PGPQQQAFQL
     LQGLEDFIAK KVEHNQRTLD PNSPRDFIDS FLIRMQEEEK NPNTEFYLKN LVMTTLNLFI
     GGTETVSTTL RYGFLLLMKH PEVEAKVHEE IDRVIGKNRQ PKFEDRAKMP YMEAVIHEIQ
     RFGDVIPMSL ARRVKKDTKF RDFFLPKGTE VFPMLGSVLR DPSFFSNPQD FNPQHFLNEK
     GQFKKSDAFV PFSIGKRNCF GEGLARMELF LFFTTVMQNF RLKSSQSPKD IDVSPKHVGF
     ATIPRNYTMS FLPR
//
